** Shares of drug developer Entrada Therapeutics TRDA.O rise 7.4% to $14 premarket
** TRDA says FDA has removed clinical hold on co's therapy, ENTR-601-44, which is being studied for a type of muscle-wasting disorder called Duschenne muscular dystrophy (DMD) in the U.S.
** Co receives authorization to initiate early-stage trial
** In December 2022, the FDA placed a clinical hold on co's application to start trials of the therapy
** Co plans to begin study enrollment in H1 2026
** In the last 12 months, TRDA has fallen ~2%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。